Udo Albus

USPTO Granted Patents = 55 (Patent Applications = 5)

CIPO Patents = 2 (Patent Applications = 6)

EPO Patents = 6 (Patent Applications = 7)

Average Co-Inventor Count = 5.9

ph-index = 10

Forward Citations = 368(Granted Patents)

Forward Citations (Not Self Cited) = 301(Dec 10, 2025)

Inventors with similar research interests:

Company Filing History:

41 out of 6,662

Hoechst Aktiengesellschaft

patents

8 out of 330

Aventis Pharma Deutschland, Gmbh

patents

5 out of 378

Bayer Pharma Aktiengesellschaft

patents

4. 3 out of 12,160

Bayer Aktiengesellschaft

patents

5. 1 out of 15

Hoeschst Aktiengesellschaft

patents

where one patent can have more than one assignee

Years Active: 1994-2024

Loading Chart...

Areas of Expertise:

Diazabicyclic Compounds

Imidazopyrimidines

Guanidines

Breathing Disorders

TASK Inhibitors

Cardiovascular Treatments

Ischemic Conditions

Benzoylguanidines

Pharmaceutical Compositions

Heterocyclic Compounds

Alkenylcarboxylic Acids

Diagnostic Aids

55 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12180227 - Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders (2024-12-31),

2. 11208422 - Substituted bridged diazepane derivatives and use thereof as TASK-1 and TASK-3 inhibitors (2021-12-28),

3. 11098063 - Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders (2021-08-24),

4. 10759794 - 2-phenyl-3-(piperazinomethyl)imidazo[1,2-A]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders (2020-09-01),

5. 10414765 - Substituted perhydropyrrolo[3,4-c]pyrrole derivatives and the use of same (2019-09-17),

6. 6703411 - Substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament containing them (2004-03-09),

7. 6632840 - Monoacyl-substituted guanidines, a process for their preparation, their use as a medicament or diagnostic aid, and pharmaceutical compositions containing them (2003-10-14),

8. 6617344 - Heterocyclically substituted benzoylguanidines, process for their preparation, their use as medicaments or diagnostics, and medicaments comprising them (2003-09-09),

9. 6600072 - Substituted 1-naphthoylguanidines, process for their preparation, their use as a medicament or diagnostic , and medicament containing them (2003-07-29),

10. 6504057 - Fluorophenyl-substituted alkenylcarboxylic acid guanidides, process for their preparation, their use as a medicament or diagnostic, and medicament containing them (2003-01-07),

11. 6436999 - Diacyl-substituted guanidines, a process for their preparation, their use as medicine or diagnostic aid, and medicine containing them (2002-08-20),

12. 6348476 - Pharmaceutical combination preparation of an inhibitor of the sodium/hydrogen exchanger and a medicament for the treatment of cardiovascular diseases (2002-02-19),

13. 6331546 - Use of 2-amino-3,4-dihydroquinazolines for the production of a medicament for the treatment or prophylaxis of illnesses caused by ischemic conditions (2001-12-18),

14. 6291502 - Use of 2-imidazolyl-substituted carbinols for the production of a medicament for the treatment or phophylaxis of diseases caused by ischemic conditions (2001-09-18),

15. 6262123 - Ortho-substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them (2001-07-17),

Title: Udo Albus: Innovator in Respiratory Disorder Treatments

Introduction

Udo Albus, based in Florstadt, Germany, is a prolific inventor with an impressive portfolio of 55 patents. His work primarily focuses on the development of novel compounds aimed at treating respiratory disorders. His contributions to the field have significant implications for the management and treatment of conditions that affect breathing, particularly during sleep.

Latest Patents

Among his latest patents, Albus has developed diazabicyclic substituted imidazopyrimidines, which are innovative compounds that show promise in the treatment of breathing disorders. These compounds are designed for use alone or in combination therapies to prevent and treat various diseases, particularly sleep-related breathing disorders such as obstructive and central sleep apnea, alongside issues like snoring.

Another significant patent involves substituted bridged diazepane derivatives, which act as inhibitors for TASK-1 and TASK-3 channels. This invention relates to the development of medications intended to address and prevent respiratory disorders, with a specific focus on sleep-related conditions. The bridging structure featured in this formula enhances the potential effectiveness of these compounds.

Career Highlights

Throughout his career, Udo Albus has worked with prominent pharmaceutical companies, including Hoechst Aktiengesellschaft and Aventis Pharma Deutschland GmbH. His extensive experience in the pharmaceutical industry has provided him with a strong foundation to innovate and develop essential therapeutic solutions.

Collaborations

Albus has collaborated with distinguished colleagues such as Andreas Gerhard Weichert and Wolfgang Scholz. This teamwork has not only expanded his research capabilities but also enriched the innovation process, leading to significant advancements in the field of respiratory treatment.

Conclusion

Udo Albus stands out as a key figure in the pharmaceutical industry, particularly in the realm of respiratory disorder treatments. His 55 patents illustrate his dedication and ingenuity, while his collaborations with notable professionals have further enhanced his contributions to healthcare. As innovations in medicine continue to evolve, the impact of Albus's inventions may play a vital role in improving the quality of life for many individuals suffering from breathing disorders.

This text is generated by artificial intelligence and may not be accurate.